Abstract

Abstract Embryonal brain tumors which include medulloblastoma and primitive neuroectodermal brain tumors (CNS-PNET) comprise the largest group of malignant pediatric brain tumors and account for substantial cancer related morbidity and mortality in childhood. Unlike medulloblastoma, a common, cerebellar PNET, few CNS-PNET arising in extracerebellar locations have been characterized. Lack of insight into the molecular pathogenesis of CNS-PNET is a major obstacle towards development of much-needed disease-specific models and treatments for these devastating tumors. In this study, we performed high-resolution DNA copy number analysis on a substantial collection of primary CNS-PNET obtained through an international collaborative group, and discovered a frequent amplicon in 25% (11/46) of CNS-PNET which span 34 protein coding genes and two miRNA clusters, C19MC and miR-371-373, on chr19q13.41. Detailed mapping studies revealed C19MC, which encode 54 primate-specific miRNAs, as the specific target of gene amplification resulting in striking tumor-specific overexpression of a sub-set of miRNAs, including miR-520 g and miR- 517c. Stable expression of miR-520 g and miR-517c promoted in vitro and in vivo oncogenicity and conferred cell survival in tumor cell lines. Strikingly expression of both miR-520g and 517c promoted growth and inhibited differentiation of untransformed normal human neural stem cells. Notably, clinicopathologic analyses revealed that C19MC amplification identifies a distinct group of CNS-PNET with similar gene expression profiles, characteristic histology, and much poorer survival. Our aggregate findings which point to C19MC as an important, new oncogenic locus in a human cancer, have significant implications for the diagnosis and clinical management of embryonal brain tumors in children. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4355.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.